Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
28 hedge funds and large institutions have $93.4M invested in Sinovac Biotech, Ltd in 2018 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 6 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
93% more capital invested
Capital invested by funds: $48.4M → $93.4M (+$45M)
4% less call options, than puts
Call options by funds: $289K | Put options by funds: $300K
3% less funds holding
Funds holding: 29 → 28 (-1)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$42.6M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$435K |
| 3 |
SCP
Seizert Capital Partners
Birmingham,
Michigan
|
+$260K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$161K |
| 5 |
YMRC
Yorktown Management & Research Company
Forest,
Virginia
|
+$37.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$615K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$547K |
| 3 |
NAH
Neumann Advisory (HK)
Central,
Hong Kong
|
-$204K |
| 4 |
SG Americas Securities
New York
|
-$179K |
| 5 |
Barclays
London,
United Kingdom
|
-$83K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $2K | +$1.88K | +260 | New |
|
|
GWM
27
Geneos Wealth Management
Englewood,
Colorado
| $1K | – | – | – |
|
28
Bank of America
Charlotte,
North Carolina
| $1K | +$678 | +94 | New |
|
|
29
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$547K | -73,337 | Closed |
|
|
30
SG Americas Securities
New York
| – | -$179K | -24,021 | Closed |
|
|
31
Barclays
London,
United Kingdom
| – | -$83K | -11,100 | Closed |
|
32
Millennium Management
New York
| – | -$76K | -10,195 | Closed |
|
SVA Hedge Fund Activity: Q3 2018 in Review
28 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q3 2018, worth a combined $93.4M — up 93% from $48.4M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of SVA and 5 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 6 added.
The largest buyer was Vivo Capital, opening a new position worth an estimated $42.6M. The largest seller was Renaissance Technologies, cutting an estimated $615K.
- 28 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q3 2018, down from 29 in Q2 2018.
- Funds reported $93.4M of Sinovac Biotech, Ltd stock for Q3 2018, up 93% quarter-over-quarter.
- 5 funds opened new Sinovac Biotech, Ltd positions in Q3 2018 and 6 closed out, a net change of -1 holder.
- The largest Sinovac Biotech, Ltd buyer in Q3 2018 was Vivo Capital, an estimated $42.6M added.
- The largest Sinovac Biotech, Ltd seller in Q3 2018 was Renaissance Technologies, an estimated $615K sold.
Based on aggregated 13F filings for Q3 2018.